Phase II trial of SGE 102 in patients with refractory status epilepticus

Trial Profile

Phase II trial of SGE 102 in patients with refractory status epilepticus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Brexanolone (Primary) ; Midazolam
  • Indications Status epilepticus
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2016 According to Sage Therapeutics media release, data presented at the. 68th American Academy of Neurology (AAN).
    • 09 Jan 2015 Interim results in 9 evaluable patients published in a SAGE Therapeutics media release.
    • 03 Nov 2014 Results in two paediatric patients published in a Sage Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top